Details
Stereochemistry | RACEMIC |
Molecular Formula | C10H14N4O3 |
Molecular Weight | 238.2432 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C
InChI
InChIKey=KYHQZNGJUGFTGR-UHFFFAOYSA-N
InChI=1S/C10H14N4O3/c1-6(15)4-14-5-11-8-7(14)9(16)13(3)10(17)12(8)2/h5-6,15H,4H2,1-3H3
Molecular Formula | C10H14N4O3 |
Molecular Weight | 238.2432 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/6291318Curator's Comment: description was created based on several sources, including
http://www.ndrugs.com/?s=ephedrine/proxyphylline
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6291318
Curator's Comment: description was created based on several sources, including
http://www.ndrugs.com/?s=ephedrine/proxyphylline
Proxyphylline is a xanthine derivative that acts as a cardiac stimulant, vasodilator and bronchodilator. In combination with ephedrine it’s used for relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema. Proxyphylline is readily absorbed from the gastrointestinal tract and it’s not converted to theophylline in the body. The clinical studies are agreed with the property of proxyphylline to inhibit the cyclic nucleotide phosphodiesterases.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363066 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6291318 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | Novofilin Approved UseUnknown |
|||
Secondary | Unknown Approved UseUnknown |
|||
Secondary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[Effectiveness of proxyphylline in chronic obstructive pulmonary disease (author's transl)]. | 1980 Jun 20 |
|
Polymer particle erosion controlling drug release. II. Swelling investigations to clarify the release mechanism. | 2002 Oct 24 |
|
The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. | 2004 May-Jun |
|
Hydrophilic molecularly imprinted poly(hydroxyethyl-methacrylate) polymers. | 2006 Jul |
|
Modifying the release of proxyphylline from PVA hydrogels using surface crosslinking. | 2008 Feb 12 |
|
Surface crosslinking for delayed release of proxyphylline from PHEMA hydrogels. | 2008 Feb 12 |
|
Synthesis, pharmacological activity and nitric oxide generation by nitrate derivatives of theophylline. | 2008 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7202475
intravenous: 29 mumol/kg
single oral: 21 mumol/kg and multiple oral: 21 mumol/kg three times a day
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6291318
Inhibition of cAMP and cGMP hydrolysis in human lung tissue by proxyphylline and its main metabolite 1-methyl-7-(beta-hydroxypropyl)xanthine was compared with theophylline and its metabolite 3-methylxanthine. The Inhibition constant of proxyphylline was 0.06-0.7 mmol/l at low cAMP concentrations and at low and high cGMP concentrations, while it was 1.0 mmol/l at high cAMP concentrations
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:11:30 GMT 2023
by
admin
on
Fri Dec 15 16:11:30 GMT 2023
|
Record UNII |
13G1DMN4P0
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R03DA03
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
||
|
WHO-VATC |
QR03DB03
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
||
|
WHO-VATC |
QR03DA03
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
||
|
WHO-ATC |
R03DB03
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
||
|
NCI_THESAURUS |
C319
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
||
|
NCI_THESAURUS |
C744
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
86480-51-5
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
SUPERSEDED | |||
|
210-028-7
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
C80339
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL37390
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
34906
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | RxNorm | ||
|
m9284
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
PROXYPHYLLINE
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
SUB10153MIG
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
4977
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
C003237
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
DB13449
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
969
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
163343
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
100000080861
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
603-00-9
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
DTXSID5023536
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
13G1DMN4P0
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
2323
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |